title: Seamless Oncology-Drug Development.
authors.affiliation: From the Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring (T.M.P., M.R.T., R.P.), and the Breast Cancer Program, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (T.M.P.) - both in Maryland.
authors.forename: Tatiana M
authors.initials: TM
authors.lastname: Prowell
authors.affiliation: From the Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring (T.M.P., M.R.T., R.P.), and the Breast Cancer Program, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (T.M.P.) - both in Maryland.
authors.forename: Marc R
authors.initials: MR
authors.lastname: Theoret
authors.affiliation: From the Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring (T.M.P., M.R.T., R.P.), and the Breast Cancer Program, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (T.M.P.) - both in Maryland.
authors.forename: Richard
authors.initials: R
authors.lastname: Pazdur
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000592:standards*; D017277:Drug Approval / Q000458:organization & administration*; D055808:Drug Discovery; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D036302:Therapeutic Human Experimentation; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C582435:pembrolizumab